Spruce Biosciences, Inc. (SPRBD)
OTCMKTS · Delayed Price · Currency is USD
9.99
-1.41 (-12.34%)
At close: Aug 8, 2025

Verve Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 20202019 - 2020
Period Ending
Mar '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2019 - 2020
2.914.9110.09---
Upgrade
Revenue Growth (YoY)
-71.28%-51.32%----
Upgrade
Cost of Revenue
46.9446.4249.4335.2--
Upgrade
Gross Profit
-44.03-41.51-39.34-35.2--
Upgrade
Selling, General & Admin
13.9814.6412.6512.0911.375.56
Upgrade
Research & Development
----30.723.85
Upgrade
Operating Expenses
13.9814.6412.6512.0942.0729.42
Upgrade
Operating Income
-58.01-56.15-51.99-47.28-42.07-29.42
Upgrade
Interest Expense
-0.25-0.31-0.48-0.42-0.35-0.32
Upgrade
Interest & Investment Income
2.83.424.561.520.120.2
Upgrade
Pretax Income
-55.45-53.04-47.92-46.18-42.29-29.54
Upgrade
Net Income
-55.45-53.04-47.92-46.18-42.29-29.54
Upgrade
Net Income to Common
-55.45-53.04-47.92-46.18-42.29-29.54
Upgrade
Shares Outstanding (Basic)
111000
Upgrade
Shares Outstanding (Diluted)
111000
Upgrade
Shares Change (YoY)
2.86%7.15%63.68%0.71%289.93%683.78%
Upgrade
EPS (Basic)
-99.08-96.39-93.32-147.21-135.78-369.78
Upgrade
EPS (Diluted)
-99.08-96.39-93.32-147.21-135.78-369.78
Upgrade
Free Cash Flow
-53.73-55.96-33.28-41.69-35.97-27.59
Upgrade
Free Cash Flow Per Share
-96.00-101.72-64.82-132.90-115.48-345.42
Upgrade
Operating Margin
-1994.16%-1143.37%-515.34%---
Upgrade
Profit Margin
-1906.22%-1079.94%-474.96%---
Upgrade
Free Cash Flow Margin
-1847.13%-1139.56%-329.88%---
Upgrade
EBITDA
-57.97-56.11-51.92-47.21-42-29.38
Upgrade
D&A For EBITDA
0.040.050.070.070.070.04
Upgrade
EBIT
-58.01-56.15-51.99-47.28-42.07-29.42
Upgrade
Source: S&P Global Market Intelligence. Standard template. Financial Sources.